BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.
Kotani D, Bando H, Taniguchi H, Masuishi T, Komatsu Y, Yamaguchi K, Nakajima T, Satoh T, Nishina T, Esaki T, Nomura S, Takahashi K, Iida S, Matsuda S, Motonaga S, Fuse N, Sato A, Fujii S, Ohtsu A, Ebi H, Yoshino T.
Kotani D, et al. Among authors: motonaga s.
ESMO Open. 2020;5(1):e000624. doi: 10.1136/esmoopen-2019-000624. Epub 2020 Sep 30.
ESMO Open. 2020.
PMID: 33551068
Free PMC article.
Clinical Trial.